Cumberland Pharmaceuticals Inc (CPIX)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$4.44+3.02%
Close 2026-11-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
Research Workspace
Put CPIX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Achieve double-digit revenue growth in 2026: Comparison needs review.
View ThesisRevenue is contracting — down about 21% over the past year.
View GrowthManagement screens weak on capital allocation, earnings delivery, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 53% in its worst 12-month stretch.
View RiskCPIX's ifetroban pipeline has to keep advancing to justify the price. Revenue growth is not yet visible in the recent results. The company remains unprofitable over the past year. It trades at 2.1 times sales versus a 2.3 times peer median. The price reflects less growth than we forecast. The primary pillar for double-digit growth is under pressure. The thesis comparison is not yet verified. Peer multiples imply a price about 62% above where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-04. CPIX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Continue this research
Compare CPIX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CPIX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put CPIX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance development of ifetroban for rare diseases
Planned NDA filing advances ifetroban development for a rare disease, though filing is not yet completed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Advance development of ifetroban for rare diseases
Reported trial results may affect ifetroban’s rare-disease development prospects.
Advance development of ifetroban for rare diseases
Phase 2a results are directly relevant, but headline alone gives no efficacy or safety details.
